Apr 17, 2019 / 03:00PM GMT
Operator
Good day, and welcome to the DURECT Corporation's KOL Call on NASH. Today's conference is being recorded.
At this time, I would like to turn the conference over to Mike Arenberg, Chief Financial Officer of DURECT Corporation. Please go ahead.
Michael H. Arenberg - DURECT Corporation - CFO
Good morning, and welcome to our Key Opinion Leader Call on Nonalcoholic Steatohepatitis, or NASH. This is Mike Arenberg, Chief Financial Officer of DURECT Corporation. This call will begin with a presentation by Dr. Brent Tetri on NASH, including an overview of the disease, its pathogenesis, current development pipeline and therapeutic targets. This will be followed by a presentation by Jim Brown, DURECT's President and CEO, on our ongoing 28-day, multidose NASH study with DUR-928, followed by a Q&A session.
Before beginning, I would like to remind you of our safe harbor statement. During the course of this call, we may make forward-looking statements regarding DURECT's business and DUR-928. These forward-looking statements involve risks and
DURECT Corporation Key Opinion Leader Call on NASH Transcript
Feb 06, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers